These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS. Mastroianni A Infez Med; 2004 Sep; 12(3):197-204. PubMed ID: 15711134 [TBL] [Abstract][Full Text] [Related]
8. Treatment of visceral leishmaniasis. Sundar S; Rai M Expert Opin Pharmacother; 2005 Dec; 6(16):2821-9. PubMed ID: 16318433 [TBL] [Abstract][Full Text] [Related]
9. [Visceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agents]. Janvier F; Morillon M; Olliaro P Med Trop (Mars); 2008 Feb; 68(1):89-101. PubMed ID: 18478781 [TBL] [Abstract][Full Text] [Related]
10. Management of visceral leishmaniasis: Indian perspective. Agrawal S; Rai M; Sundar S J Postgrad Med; 2005; 51 Suppl 1():S53-7. PubMed ID: 16519257 [TBL] [Abstract][Full Text] [Related]
11. Drug resistance in Indian visceral leishmaniasis. Sundar S Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838 [TBL] [Abstract][Full Text] [Related]
12. Treatment of visceral leishmaniasis: a review of current treatment practices. Marty P; Rosenthal E Expert Opin Pharmacother; 2002 Aug; 3(8):1101-8. PubMed ID: 12150689 [TBL] [Abstract][Full Text] [Related]
14. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967 [TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377 [TBL] [Abstract][Full Text] [Related]
16. Treatment of leishmaniasis in HIV-positive patients. Laguna F Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640 [TBL] [Abstract][Full Text] [Related]
17. Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens. van Griensven J; Diro E Infect Dis Clin North Am; 2019 Mar; 33(1):79-99. PubMed ID: 30712769 [TBL] [Abstract][Full Text] [Related]
18. Visceral leishmaniasis - current therapeutic modalities. Sundar S; Chatterjee M Indian J Med Res; 2006 Mar; 123(3):345-52. PubMed ID: 16778315 [TBL] [Abstract][Full Text] [Related]
19. Treatment of visceral leishmaniasis in 2004. Murray HW Am J Trop Med Hyg; 2004 Dec; 71(6):787-94. PubMed ID: 15642973 [TBL] [Abstract][Full Text] [Related]
20. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Murray HW Int J Infect Dis; 2000; 4(3):158-77. PubMed ID: 11179920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]